To see all protocols that comply with the WHO Essential Medicine List 
This protocol has been superseded as the locoregional rates have inferior outcomes when compared to hypofractionated / accelerated regimens such as those reported in the DAHANCA RCTs.

Note: According to randomised control trials (Overgaard 2003 - DAHANCA, Yamazaki 2006), this protocol has been shown to have inferior outcomes.

Improved locoregional control rates have been reported with hypofractionated/ accelerated schedules and therefore the use of hypofractionated/accelerated protocols over conventional schedules is strongly recommended. Link to Head and neck early glottic larynx squamous cell carcinoma definitive EBRT

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

15 Oct 2019